Institutional Review Board (IRB)

What is an Institutional Review Board (IRB)?

An Institutional Review Board (IRB) is an administrative body charged with the protection of the rights, safety, and welfare of human subjects in research. The IRB is charged with the responsibility of reviewing and approving, prior to its initiation and thereafter on an ongoing basis, all research (whether funded or not) involving human participants. The IRB has the authority to approve, disapprove, monitor, suspend, terminate, and/or require modifications to all human subjects research activities that fall within its jurisdiction under the federal research regulations and institutional policy.
 
Institutional Review Boards are charged with ensuring that:

  • Research is conducted according to well-designed protocols likely to advance scientific knowledge
  • The participation of human subjects in research is voluntary and complies with the statutory requirements for informed consent
  • Risks to study subjects are minimized and outweighed by potential benefits to subjects and/or society

Creighton University Institutional Review Boards

Creighton University IRB (CU IRB) is responsible for all human subjects research conducted by CU faculty or students or occurring on a CU campus. CU IRB has two review boards, a Biomedical IRB (IRB-01) and a Social and Behavioral IRB (IRB-02). Creighton’s IRBs operate under Federal Wide Assurance (FWA) FWA00001078. A Federal Wide Assurance is an assurance of compliance provided from an institution to the federal government, attesting that the institution will abide by the federal human subjects research regulations.

Members are appointed to the CU IRBs by the CU Institutional Official, Julie Strauss-Soukup, PhD.

Standard IRB Turnaround Times

The IRB aims to complete its initial review of complete IRB submissions (no missing documents or information) consistent with or faster than median turnaround times for Association for the Accreditation of Human Research Protections (AAHRPP) accredited programs, which are listed below.
 
While we endeavor to complete our review well ahead of these expected turnaround times, a faster review will not always be possible. Therefore, we encourage investigators to be aware of anticipated turnaround times and to communicate with the IRB Office if priority review is requested to meet deadlines associated with a grant application, course requirements, etc. Please note that priority review is never guaranteed.
 
In addition, anticipated turnaround times apply to complete submissions only. If your submission is missing required information or requires revision it will be returned to you with comments via the InfoEd platform. In these cases, turnaround time calculations begin once your complete/revised submission has been successfully returned to the IRB. During periods of the academic year when the IRB is reviewing a higher-than-average volume of submissions, the IRB will post a notice about expected turnaround times to this website. If you believe that your submission is not adhering to the turnaround times below, please contact the IRB Office at irb@creighton.edu or 402.280.2126.

Initial Applications (Quality Improvement (QI), Not Human Subjects Research (NHSR), or Exempt submissions) 

Within 12 business days.

Initial Applications (Expedited Studies)

Within 17 business days.

Initial Application (Full Board, Greater than Minimal Risk Studies) 

Are due to the IRB two weeks prior to the dates of the next convened IRB meeting. The IRB meeting schedule and information on full Board submission deadlines can be located here. Protocols received within one week prior to the next meeting may be added to the meeting agenda at the discretion of the IRB Director and IRB Chair. Protocols received with less than one week prior to the meeting agenda will be added to the meeting agenda for the following month. Please understand that compliance with the human research regulations requires that Board members have adequate time to read and evaluate submissions prior to the date of the convened meeting.

Modifications (NOT REQUIRING Scientific Review) 

Within 5 business days.

Modifications (REQURING Scientific Review) 

Within 12 business days.

  • This includes submissions with revised investigators brochures or other updated drug or device information, revisions to biomedical protocols that may increase risks to subjects or others.

Prompt Reporting Events (Subject Death, Hospitalization, or Other Serious Adverse Events (SAEs))

Within 48 hours.

Prompt Reporting Events (Other)

Within 5 business days UNLESS the RNI submission is limited to a single site visit monitoring report, in which case the report must be submitted within 30 days.

Closure (Routine Study Closeout)

Within 5 business days.

Continuing Review (Expedited Studies subject to FDA regulation ONLY)

Within 7 business days.

Continuing Review (Full Board Greater than Minimal Risk Studies): Are due to the IRB office no later than 30 days prior to the date of expiration for the IRB protocol to ensure that continuing reviews can be added to the next regularly scheduled IRB meeting. Late-submitted requests for continuing review may lead to a lapse in IRB approval. If IRB approval is permitted to lapse, no study activities other than those necessary to protect the rights, safety, and welfare of subjects will be allowed to continue and study enrollment must be stopped until IRB approval has been restored.


IRB Office Contact Information
Location: Dr. C.C. and Mabel L. Criss Health Sciences Complex I, Room 111
Phone: 402.280.2126
Fax: 402.280.4766
Email: IRB@creighton.edu

IRB Meeting Schedules

The Institutional Review Boards at Creighton University convene on a regular basis to review research involving human subjects.

The Biomedical Institutional Review Board and Social Behavioral Institutional Review Board meet in the Research and Compliance Conference Room, Criss 1, Room 111A. IRB members and investigators attending Creighton University IRB meetings may choose to attend either in person or via Zoom.

Questions regarding IRB meeting schedules, submission deadlines, or meeting attendance via Zoom should be directed to the IRB Office at 402.280.2126 or via email at IRB@creighton.edu.

Becoming a Research Participant

If you are participating in research at Creighton University or thinking about it, this site may provide helpful information about your rights, how to find a study, helpful links, and how to get your questions answered.

If you are a prospective or current participant and would like to speak with someone unaffiliated with a specific research study in order to ask questions about participating in research, obtain information about participating in research, or offer input, please contact the IRB Office at 402.280.2126 or by email at IRB@creighton.edu

If you are not happy with the way a study is being conducted at Creighton University, you may complain (anonymously, if you choose) to the IRB Office by calling 402.280.2126 or emailing IRB@creighton.edu, by calling the Research Compliance Hotline 855.256.0478, emailing the Director of Research Compliance at JoeK@creighton.edu, or addressing a letter to:
Institutional Review Board
Creighton University
2500 California Plaza
Omaha, NE 68178

Your Responsibilities as a Research Participant

  • Completely read the consent form and ask the Principal Investigator (the person in charge of the study) any questions you may have. You should understand what will happen to you during the study before you agree to participate.
  • Know the dates when your study participation starts and ends.
  • Carefully weigh the possible benefits (if any) and risks of being in the study.
  • Talk to the Principal Investigator if you want to stop being part of the research study.
  • Contact the Principal Investigator and/or the Creighton University Institutional Review Board with complaints or concerns about your participation in the study.
  • Report to the Principal Investigator immediately any and all problems you may be having with the study drug/procedure/device.
  • Fulfill the responsibilities of participation as described on the consent forms unless you are stopping your participation in the study.
  • Tell the Principal Investigator or the person you are working with on the study when you have received the compensation you were promised for participating in the study.
  • Ask for the results of the study, if you want them.
  • Keep a copy of the consent form for your records.

The Principal Investigator's Responsibilities

The Principal Investigator is the individual who is responsible for a research study. The Principal Investigator is required to:

  • Follow the Creighton University IRB-approved research study plan.
  • Obtain informed consent from all study participants.
  • Maintain the confidentiality of study participants.
  • Quickly respond to all participant concerns and questions.
  • Tell participants about changes to the risks or benefits of the study.
  • Get approval from the Creighton University IRB for any changes to the study.
  • Promptly report all unanticipated problems or research-related injuries to the IRB.
  • Per policy, keep research records for seven (7) years after the study is over.
  • Effectively train/mentor student researchers in ethical conduct of research.
  • Comply with all Creighton University procedures for the ethical conduct of human subject research.

Additional Research Participant Topics

Adverse Event: Complications or drug side effects that may occur during the research study. An anticipated adverse event is known to occur from past experience with the treatment. An unanticipated adverse event is an unexpected complication. These events may or may not be related to your participation in the research study, and will be closely monitored and recorded by the Principal Investigator. 

Assent: Acknowledgement from a child that they want to participate in a research study. Assent is obtained from children older than 7 years of age (where possible) and permission is obtained from the child’s parent(s) or legal guardian(s).

Bias: Factors, such as human choice or opinion, that may affect the results of the study when, in reality, these factors are not related to the treatment under study. 

Blinded: An approach to avoid bias, when a researcher and/or study participant is not aware of whether the study participant is on the drug being studied or a placebo. 

Biomedical: Having to do with the life sciences, medicine, dentistry, nursing, and public health.

Clinical Trial: A carefully controlled and developed study or research study designed to test and evaluate new drugs or treatment plans. 

Clinical Research: Medical research that may involve patients and sometimes healthy volunteers. These research studies are designed to uncover better ways to treat, prevent, diagnose, and understand human disease. Sometimes they help patients feel or get better but sometimes they don’t. In rare cases, the studies can make patients worse.

Cognitive Impairment: Reduction in mental functioning and ability to carry out tasks that require thinking, planning, and memory. This may include those who use drugs or alcohol, suffer from a disease that affects the brain, are terminally ill, and have severe physical handicaps. These groups of people may not be able to make decisions in their best interest. 

Confidentiality: Refers to how the information that a research participant has given to the investigators is handled; this information is normally given with the expectation that it will not be given to others without the participant’s permission.

Identifiable Private Information: Information that can identify an individual, including: name, birth date, Social Security number, address, telephone number, email address, computer ID, and others.

Inclusion/Exclusion Criteria: The predetermined criteria that are used to select the correct participants for the study. These include the presence or absence of certain conditions, medications, or physical characteristics. 

Informed Consent: The dialogue between potential participants and researchers that takes place before anyone decides whether to take part in a study. This process of communication should be free of pressure or rushing, should include all key information, and a chance to ask questions and have them answered. Informed consent can be more than just a one-time conversation. As a study goes on, participants can renew their agreement to be in the study, and they can also decide to quit without penalty. The important thing is open and clear communication. This process includes signing an Informed Consent Form that describes the risks and benefits that may occur if the person decides to take part in the study. 

Informed Consent Form (ICF): The form participants sign to agree to be in the study. The ICF includes details about the study, such as its purpose, duration, required procedures, risk, benefits, and who to contact for further information. Sometimes, a signature is not needed, but participants may still keep a copy of the ICF. In these cases it may be called an Information Sheet instead, but the contents are the same. The ICF is not a contract. Participants do not give up any legal rights by signing an ICF. Participants are free to withdraw at any time.

Institutional Review Board (IRB): A group of scientists, doctors, and lay persons who review each clinical research study before it starts to ensure that the study is well-designed, does not involve unnecessary risks, and ensures the safety of participants.

Investigator: A scientist who is working on a research study to answer certain questions, test a theory, or explore a new area in hopes of designing a future study. Also called a researcher. 

National Institutes of Health (NIH): An agency within the U.S. Department of Health and Human Services that provides funding for research and conducts studies.

Oral Consent: Written information that describes what will be told to research participants who cannot read or feel uncomfortable signing forms for cultural reasons.

Parent/Guardian Permission: This form is signed by parents/legal guardians in order to allow children to participate in a study. For children 7 and older, an assent form is also provided to the child.

Phases: The steps of a clinical trial. Usually describes the type of study and is an indication of the degree of knowledge that has been obtained on the drug. 

Placebo: An inactive substance that may resemble an active drug but has no medical value. 

Principal Investigator (PI): The chief researcher on a study. The PI is responsible for everything that takes place in a study.

Protected Health Information (PHI): Health information that can identify an individual, including: name, birth date, Social Security number, address, telephone number, email address, computer ID, medical record number, and others.

Protocol: The scientific plan of the research study. A protocol describes the purpose of the study, who is eligible to participate, details about the research procedures, the length and steps of the study, and what information will be gathered.

Research: An organized way of finding out about something. Most scientists conduct research, but not all research involves human volunteers. Most research is done with the hope of learning something valuable enough to share with others by publishing articles in scientific journals. Research can turn up both expected and unexpected results. Research usually involves some sort of risk-taking, whether small or great. 

Research Study: This is a kind of study that is developed to answer a basic question on any subject, such as testing a new drug or treatment or comparing commonly used interventions. 

Research Participants (or Research Subjects): The participants in a research study. These individuals voluntarily agree to participate in the study. 

Risk versus Benefit: A comparison of the risks involved for the research participants and whether the expected benefits justify those risks. 

Social-Behavioral: Involving the social sciences, the formal study of societies and human behavior. The areas of anthropology, sociology, psychology, religion, and political science are examples of disciplines that may conduct research of this kind. Common ways of collecting information include surveys, focus groups, interviews, and observing behavior in a specially designed setting.

Sponsor: The organization that oversees and pays for the study or provides in-kind support (like medications). This can be a single person, a charitable foundation, a medical institution, a drug-making company, or a federal agency like the National Institutes of Health or Department of Defense.

Unanticipated Problem: Any problem that happens during a study that is related to the research and was not predicted to happen.

U.S. Food and Drug Administration (FDA): A department in the U.S. Department of Health and Human Services. The FDA ensures the safety of prescription and non-prescription drugs and medical devices in the United States, including those that are being tested by research studies and clinical trials.

  • Why is the research being done?
  • What will be done to me as part of the research?
  • How will I benefit from the research?
  • Could the research hurt me?
  • What will the researcher do with my information?
  • Will the research cost me anything?
  • Who pays if I’m unexpectedly injured during the study?
  • How long will the study last?
  • What happens if I decide to leave the study early?
  • Who should I call if I have a question about the research?

Your feedback on your experience as a research participant is valuable to us. With it, we can ensure that our research studies are conducted in the best manner possible, and we can try to improve the experience for other participants. If you are currently participating in a study, or have participated in past studies, please take a moment to fill out this survey.

Creighton University IRB Office

Nancy McCormick, MS, CCRC, CIP
IRB Director
Email: NancyMcCormick@creighton.edu 


Betsy Dancisak, MPH, CIP
Senior IRB Administrator
Email: BetsyDancisak@creighton.edu 


Meg Rayner, MPH, CIP
Senior IRB Administrator
Email: MegRayner@creighton.edu 


Teri Prentis, BA
IRB/IBC Administrator
Phone: 402-280-2126
Email: TeriPrentis@creighton.edu 

Image

AAHRPP Accreditation

Creighton University Earns Full AAHRPP Accreditation
Creighton joins an elite group of organizations in achieving full accreditation from the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP). In achieving full AAHRPP accreditation, Creighton University has demonstrated its commitment to rigorous standards that help protect research participants while ensuring that society continues to reap the benefits of research.


Creighton University IRB Regulatory Information

FWA number: 00001078
IRB registration numbers:
Creighton U IRB #1 – Biomedical IRB00000155
Creighton U IRB #2 – Social Behavioral IRB00007137
IORG number: 0000096